Concomitant background medication usage may influence the observed risk of acute pancreatitis or pancreatic cancer, either through confounding or diluting the risk attributable to GLP‐1 RAs [8, 9, 10, 11]. The gene discussed is GCG; the disease is acute pancreatitis.